Vertex Pharmaceuticals (VRTX) Raw Materials (2011 - 2012)
Vertex Pharmaceuticals (VRTX) posted quarterly Raw Materials of $4.5 million for Q3 2012, down 77.58% year-over-year from $20.1 million in Q4 2011, and down 11.21% quarter-over-quarter from $5.1 million in Q2 2012.
Powered by 
Analysis
Vertex Pharmaceuticals (VRTX) Raw Materials (2011 - 2012) Analysis & Trends
Vertex Pharmaceuticals' Raw Materials history runs 2 years deep, the most recent figure standing at $4.5 million for Q3 2012.
- In Q3 2012, Raw Materials fell 77.58% year-over-year to $4.5 million; the TTM figure through Sep 2012 stood at $4.5 million (down 77.58% YoY), while the FY2011 annual figure was $32.2 million, changed N/A from the prior year.
- Raw Materials for Q3 2012 stood at $4.5 million, down from $5.1 million in the prior quarter.
- The five-year high for Raw Materials was $32.2 million in Q4 2011, with the low at $4.5 million in Q3 2012.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.70 Bn | 58.52 Bn | 1.37 Bn |
| 4 | Moderna | 57.56 Bn | 52.42 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 40.16 Bn | 35.06 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.63 Bn | 32.32 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.63 Bn | 27.79 Bn | - |
| 9 | Insmed | 27.73 Bn | 26.57 Bn | 358.27 Mn |
| 10 | Incyte | 25.60 Bn | 21.07 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2012 | 4.51 Mn |
| Jun 30, 2012 | 5.08 Mn |
| Mar 31, 2012 | 28.51 Mn |
| Dec 31, 2011 | 32.21 Mn |
| Sep 30, 2011 | 20.10 Mn |
| Mar 31, 2011 | 7.82 Mn |